Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 5, 2014, Pages 601-606

  Morgan, Matt ^a,b   Cooke, Andrew ^a   Rogers, Laura ^a,c   Adams Huet, Beverley ^d   Khan, David A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Allergy Asthma and Immunology of North Texas   (United States)

^c Chicago Lake Shore Allergy and Asthma   (United States)

^d UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Antihistamine; Chronic idiopathic urticaria; Dapsone; RCT; Urticaria

Indexed keywords

DAPSONE; PLACEBO; ANTIALLERGIC AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST;

ADULT; AGED; ANTIHISTAMINE REFRACTORY CHRONIC IDIOPATHIC URTICARIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERANCE; FEMALE; HUMAN; MALE; NAUSEA; NEUROPATHY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN PRURITUS; TREATMENT DURATION; TREATMENT OUTCOME; URTICARIA; VAGINA CANDIDIASIS; VIRAL RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; CHRONIC DISEASE; CROSSOVER PROCEDURE; DRUG RESISTANCE; MIDDLE AGED;

ADULT; ANTI-ALLERGIC AGENTS; CHRONIC DISEASE; CROSS-OVER STUDIES; DAPSONE; DOUBLE-BLIND METHOD; DRUG RESISTANCE; FEMALE; HISTAMINE H1 ANTAGONISTS; HUMANS; MALE; MIDDLE AGED; URTICARIA;

EID: 84925108209     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.06.004     Document Type: Article

References (38)

1. Zuberbier T., Asero R., Bindslev-Jensen C., Walter Canonica G., Church M.K., Gimenez-Arnau A., et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009, 64:1417-1426.
2. O'Donnell B.F., Lawlor F., Simpson J., Morgan M., Greaves M.W. The impact of chronic urticaria on the quality of life. Br J Dermatol 1997, 136:197-201.
3. Khan D.A. Chronic urticaria: diagnosis and management. Allergy Asthma Proc 2008, 29:439-446.
4. Powell R.J.T.G., Leech S.C., Dixon T.A., Clark A.T., Mirakian R. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy 2007, 37:631-650.
5. Greaves M. Chronic urticaria. JAllergy Clin Immunol 2000, 105:664-672.
6. Maurer M., Weller K., Bindslev-Jensen C., Gimenez-Arnau A., Bousquet P.J., Bousquet J., et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy 2011, 66:317-330.
7. Zuberbier T., Asero R., Bindslev-Jensen C., Walter Canonica G., Church M.K., Gimenez-Arnau A.M., et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009, 64:1427-1443.
8. Kaplan A.P. Clinical practice. Chronic urticaria and angioedema. NEngl J Med 2002, 346:175-179.
9. Trojan T.D., Khan D.A. Calcineurin inhibitors in chronic urticaria. Curr Opin Allergy Clin Immunol 2012, 12:412-420.
10. Kaplan A., Ledford D., Ashby M., Canvin J., Zazzali J.L., Conner E., et al. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. JAllergy Clin Immunol 2013, 132:101-109.
11. Maurer M., Rosen K., Hsieh H.J., Saini S., Grattan C., Gimenez-Arnau A., et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. NEngl J Med 2013, 368:2340-2341.
12. Bonney R.J., Wightman P.D., Dahlgren M.E., Sadowski S.J., Davies P., Jensen N., et al. Inhibition of the release of prostaglandins, leukotrienes and lysosomal acid hydrolases from macrophages by selective inhibitors of lecithin biosynthesis. Biochem Pharmacol 1983, 32:361-366.
13. Bozeman P.M., Learn D.B., Thomas E.L. Inhibition of the human leukocyte enzymes myeloperoxidase and eosinophil peroxidase by dapsone. Biochem Pharmacol 1992, 44:553-563.
14. Booth S.A., Moody C.E., Dahl M.V., Herron M.J., Nelson R.D. Dapsone suppresses integrin-mediated neutrophil adherence function. JInvestig Dermatol 1992, 98:135-140.
15. Wozel G., Lehmann B. Dapsone inhibits the generation of 5-lipoxygenase products in human polymorphonuclear leukocytes. Skin Pharmacol 1995, 8:196-202.
16. Chren M.M., Lasek R.J., Flocke S.A., Zyzanski S.J. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997, 133:1433-1440.
17. Zhu Y.I., Stiller M.J. Dapsone and sulfones in dermatology: overview and update. JAm Acad Dermatol 2001, 45:420-434.
18. Lorenz M., Wozel G., Schmitt J. Hypersensitivity reactions to dapsone: a systematic review. Acta Derm Venereol 2012, 92:194-199.
19. Matthews C.N., Saihan E.M., Warin R.P. Urticaria-like lesions associated with systemic lupus erythematosus: response to dapsone. Br J Dermatol 1978, 99:455-457.
20. Cassano N., D'Argento V., Filotico R., Vena G.A. Low-dose dapsone in chronic idiopathic urticaria: preliminary results of an open study. Acta Derm Venereol 2005, 85:254-255.
21. Engin B., Ozdemir M. Prospective randomized non-blinded clinical trial on the use of dapsone plus antihistamine vs. antihistamine in patients with chronic idiopathic urticaria. JEur Acad Dermatol Venereol 2008, 22:481-486.
22. Mutasim D.F. Management of autoimmune bullous diseases: pharmacology and therapeutics. JAm Acad Dermatol 2004, 51:859-877. quiz 78-80.
23. Gordon R.A., Mays R., Sambrano B., Mayo T., Lapolla W. Antibiotics used in nonbacterial dermatologic conditions. Dermatol Ther 2012, 25:38-54.
24. Kirtschig G., Murrell D., Wojnarowska F., Khumalo N. Interventions for mucous membrane pemphigoid and epidermolysis bullosa acquisita. Cochrane Database Syst Rev 2003, (1):CD004056.
25. Knudson R.M., Kalaaji A.N., Bruce A.J. The management of mucous membrane pemphigoid and pemphigus. Dermatol Ther 2010, 23:268-280.
26. Reed J., Wilkinson J. Subcorneal pustular dermatosis. Clin Dermatol 2000, 18:301-313.
27. Yasuda H., Kobayashi H., Hashimoto T., Itoh K., Yamane M., Nakamura J. Subcorneal pustular dermatosis type of IgA pemphigus: demonstration of autoantibodies to desmocollin-1 and clinical review. Br J Dermatol 2000, 143:144-148.
28. Kuhn A., Ruland V., Bonsmann G. Cutaneous lupus erythematosus: update of therapeutic options part I. JAm Acad Dermatol 2011, 65:e179-e193.
29. Paramkusam G., Meduri V., Gangeshetty N. Pyoderma gangrenosum with oral involvement: case report and review of the literature. Int J Oral Sci 2010, 2:111-116.
30. Hasselmann D.O., Bens G., Tilgen W., Reichrath J. Pyoderma gangrenosum: clinical presentation and outcome in 18 cases and review of the literature. JDtsch Dermatol Ges 2007, 5:560-564.
31. Lin P., Liang G. Behçet disease: recommendation for clinical management of mucocutaneous lesions. JClin Rheumatol 2006, 12:282-286.
32. Byrd S.R., Gelber R.H. Effect of dapsone on haemoglobin concentration in patients with leprosy. Lepr Rev 1991, 62:171-178.
33. Grindulis K.A., McConkey B. Rheumatoid arthritis: the effects of treatment with dapsone on hemoglobin. JRheumatol 1984, 11:776-778.
34. Barclay J.A., Ziemba S.E., Ibrahim R.B. Dapsone-induced methemoglobinemia: a primer for clinicians. Ann Pharmacother 2011, 45:1103-1115.
35. Coleman M.D. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology 2001, 162:53-60.
36. Hornsten P., Keisu M., Wiholm B.E. The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990, 126:919-922.
37. Kosseifi S.G., Guha B., Nassour D.N., Chi D.S., Krishnaswamy G. The dapsone hypersensitivity syndrome revisited: a potentially fatal multisystem disorder with prominent hepatopulmonary manifestations. JOccup Med Toxicol 2006, 1:9.
38. Bernstein J.A., Lang D.M., Khan D.A., Craig T., Dreyfus D., Hsieh F., et al. The diagnosis and management of acute and chronic urticaria: 2014 update. JAllergy Clin Immunol 2014, 133:1270-1277.